ALEXION PHARMACEUTICALS, INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
Phase 3
Terminated
- Conditions
- Thrombotic Microangiopathy
- Interventions
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04743804
- Locations
- π¬π§
Research Site, Stevenage, United Kingdom
A Study of ALXN1830 in Healthy Adult Participants
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04730804
- Locations
- π³πΏ
Research Site, Grafton, New Zealand
π³πΏClinical Trial Site, Auckland, New Zealand
A Drug Interaction Study of Danicopan
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04709094
- Locations
- πΊπΈ
Clinical Study Site, Tempe, Arizona, United States
A Drug Interaction Study of ACH-0145228
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT04709081
- Locations
- πΊπΈ
Clinical Study Site, Tempe, Arizona, United States
A Study of the Cardiac Effects of ALXN2050 in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04660890
- Locations
- πΊπΈ
Clinical Trial Site, Tempe, Arizona, United States
Study of ALXN1820 in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ALXN1820 SCDrug: Placebo SCDrug: ALXN1820 IVDrug: Placebo IV
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT04631562
- Locations
- π¬π§
Research Site, London, United Kingdom
Study of ALXN2050 in Participants With Renal Impairment
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04623710
- Locations
- πΊπΈ
Clinical Trial Site, Orlando, Florida, United States
A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM
Phase 3
Active, not recruiting
- Conditions
- Symptomatic Transthyretin Amyloid Cardiomyopathy
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04622046
- Locations
- π―π΅
Research Site, Suita-shi, Japan
Bioavailability Study of 2 Oral Formulations of ALXN1840
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04610580
- Locations
- π¦πΊ
Nucleus Network Pty Ltd., Melbourne, Victoria, Australia
Study of the Metabolism of Danicopan in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04609696
- Locations
- πΊπΈ
Clinical Trial Site, Tempe, Arizona, United States
Β© Copyright 2025. All Rights Reserved by MedPath